Climb Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $740.98M
- P/E (TTM)
- –
- Dividend yield
- –
About Climb Bio
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology business that develops therapies for individuals suffering from immune-mediated conditions. Its pipeline centers on two investigational monoclonal antibodies obtained through acquisitions and licensing: budoprutug and CLYM116. Budoprutug targets CD19 to deplete B cells in conditions such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116 targets APRIL to suppress antibody production in immunoglobulin A nephropathy and related disorders. The company's end users are patients with serious autoimmune and inflammatory diseases.
The company conducts clinical development programs across several continents. It maintains or prepares trial sites in the United States, Australia, China, Argentina, Brazil, Georgia, Taiwan, Bulgaria, Greece, Serbia, Spain, Romania, and Ukraine. Additionally, it collaborates with a development partner located in China. The provided text does not disclose the location of the company's headquarters or its physical facilities.
Summary of the business section of Climb Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Climb Bio, Inc.
- Headquarters
- Wellesley Hills, MA
- Address
- 20 William Street, Suite G50
- Phone
- 1-866-857-2596
- Website
- climbbio.com
- Employees
- 28, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Seattle, Washington
Stock & identifiers
- Ticker
- CLYM
- Exchange
- Nasdaq
- IPO date
- Aug 11, 2021
- Shares outstanding
- 57M, Jul 31, 2026
- Public float
- $44.80M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1768446
- CUSIP
- 28658R106
- ISIN
- US28658R1068
- EIN
- 83-2273741
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Aoife Brennan | President and CEO, Director | 87,731 |
| Susan ALTSCHULLER | Chief Financial Officer | – |
| Perrin Megan Wilson | Chief Business Officer | – |
| Cindy Driscoll | Senior Vice President, Finance | – |
| Emily Pimblett | SVP, Finance & CAO | 18,888 |
| Brett Kaplan | Chief Operating Officer | – |
| RA Capital Nexus Fund II, L.P. | Director | 288,461 |
| Capital Healthcare Fund LP RA | Director | 3,403,429 |
| Rajeev M. Shah | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Peter Kolchinsky | Director | 3,396,318 |
| RA Capital Nexus Fund, L.P. | Director | 20,000 |
| Ra Capital Management, L.P. | Director | – |
| Stephen Basil Thomas | Director | 467,969 |
| Breanna Maurine Celebi | Director | – |
| Andrew David Levin | Director | 0 |
| Douglas E. Williams | Director | – |
| Alexander Cumbo | Director | – |
| Kimberlee C. Drapkin | Director | – |
| Judith Dunn | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 28 full-time employees, and one part-time employee, including a total of six employees with M.D., Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 20, 2024 | Name change | Name changed from Eliem Therapeutics, Inc. to Climb Bio, Inc. |
| Jun 27, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 4, 2024 | Merger vote | Definitive merger proxy statement |
| Aug 11, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 3, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |